Chartwell Investment Partners LLC Sells 4,235 Shares of Hologic, Inc. (NASDAQ:HOLX)

Chartwell Investment Partners LLC reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 12.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,611 shares of the medical equipment provider’s stock after selling 4,235 shares during the period. Chartwell Investment Partners LLC’s holdings in Hologic were worth $2,331,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Innealta Capital LLC purchased a new stake in shares of Hologic during the second quarter worth about $25,000. Wolff Wiese Magana LLC purchased a new stake in Hologic in the third quarter worth about $25,000. iA Global Asset Management Inc. purchased a new stake in Hologic in the first quarter worth about $37,000. Sunbelt Securities Inc. purchased a new stake in Hologic in the second quarter worth about $37,000. Finally, Cromwell Holdings LLC lifted its holdings in Hologic by 330.2% in the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 416 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

HOLX has been the subject of several research analyst reports. Citigroup lowered shares of Hologic from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $95.00 to $85.00 in a report on Tuesday, October 1st. Leerink Partners lowered their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Raymond James raised their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an “outperform” rating in a report on Tuesday, November 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Finally, Royal Bank of Canada raised their target price on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $89.25.

Hologic Price Performance

Shares of HOLX opened at $79.76 on Wednesday. The company has a market capitalization of $18.53 billion, a P/E ratio of 23.95, a price-to-earnings-growth ratio of 2.48 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.69 and a debt-to-equity ratio of 0.49. The firm has a 50 day moving average of $80.88 and a 200 day moving average of $78.22. Hologic, Inc. has a twelve month low of $67.59 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The company’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.89 EPS. As a group, equities research analysts anticipate that Hologic, Inc. will post 4.27 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.